Peking University Traditional Chinese Medicine Clinical Medical School (Xiyuan), Peking University Health Science Center, Beijing, 100091, China.
Peking University Health Science Center, Beijing, 100191, China.
Mol Cancer. 2024 Aug 8;23(1):161. doi: 10.1186/s12943-024-02077-w.
This commentary offers a thoughtful discussion of the study by Wei et al. published in the journal on the role of Olfactomedin 4 (OLFM4) in incomplete intestinal metaplasia, a gastric precancerous condition. The original paper introduces OLFM4 as a novel biomarker with potential enhanced diagnostic efficacy compared to established markers. However, several methodological and interpretive considerations are noted. The histopathological findings could be refined by using higher magnification to better elucidate the cellular localization of OLFM4. Including high-resolution images for key stainings would enhance the study's robustness in expression profiling. The statistical approach could be strengthened by employing more rigorous, quantitative methodologies. Additionally, integrating immunofluorescence double-staining may improve the reliability of the results. Discrepancies in immunohistochemical signals across datasets suggest a need for further investigation into tissue section representativeness. Clarifying the term "precancerous lesions of gastric carcinoma cells" to align with widely accepted definitions would enhance clarity. The choice of the GES-1 cell model treated with MNNG could be reconsidered in favor of more established models such as organoids, air-liquid interface models, and gastric cancer-specific cell lines. The in vivo MNNG-alcohol combination model might require additional empirical support, given the limited and conflicting literature on this approach, to ensure an accurate portrayal of IM pathogenesis. The commentary concludes with a call for stringent and standardized methodologies in biomarker research to ensure the clinical applicability and reliability of biomarker studies, particularly in the context of gastric cancer detection and intervention.
这篇评论对 Wei 等人在该杂志上发表的关于 Olfactomedin 4（OLFM4）在不完全肠上皮内瘤变（一种胃癌前病变）中的作用的研究进行了深入探讨。原始论文介绍了 OLFM4 作为一种新型生物标志物，与已建立的标志物相比，具有潜在的增强诊断效果。然而，也注意到了几个方法学和解释性的考虑因素。通过使用更高的放大倍数，可以更好地阐明 OLFM4 的细胞定位，从而细化组织病理学发现。包括关键染色的高分辨率图像将增强表达谱研究的稳健性。通过采用更严格、定量的方法可以加强统计方法。此外，整合免疫荧光双重染色可能会提高结果的可靠性。数据集之间免疫组织化学信号的差异表明需要进一步研究组织切片的代表性。将术语“胃癌细胞癌前病变”澄清为与广泛接受的定义一致，将提高清晰度。MNNG 处理的 GES-1 细胞模型的选择可以重新考虑，转而使用更成熟的模型，如类器官、气液界面模型和胃癌特异性细胞系。由于关于这种方法的文献有限且存在冲突，体内 MNNG-酒精联合模型可能需要额外的经验支持，以确保对 IM 发病机制的准确描述。评论最后呼吁在生物标志物研究中采用严格和标准化的方法，以确保生物标志物研究的临床适用性和可靠性，特别是在胃癌检测和干预方面。
